8.

R1

H

N

H

N

O

R2

O

R3

O

The morpholin-3-one-fused quinazoline derivatives have

efficient binding with the c-Raf (active site)

Palumbo

et al. (2016)

9.

R1

Br

H2N

O

O

O

H

N

R2

R3

H

First-generation EGFR inhibitor having six times more EGFR

inhibitory potential

Zheng et al.

(2017)

10.

Second-generation EGFR inhibitor with comparable

anticancer activity

Tu et al.

(2017)

11.

First-generation EGFR inhibitor. It is more potent than

lapatinib for EGFR inhibition

Chen et al.

(2017)

12.

First-generation inhibitor. Lesser potent than gefitinib and is

moderately cytotoxic

Hou et al.

(2016)

13.

First-generation inhibitor. Produces synergistic effect and is a

potent anticancer drug

Ding et al.

(2017)

14.

First-generation inhibitor. Lesser potent than gefitinib and is

moderately cytotoxic

Hou et al.

(2016)

(continued)

21

EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents

391